ArticleCell & bioscience2023
METTL3-mediated m6A methylation regulates ovarian cancer progression by recruiting myeloid-derived suppressor cells.
Article in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- N6 methyl adenosine-stabilized microtubule actin crosslinking factor 1 ameliorates staphylococcal protein A-induced damage in osteocyte-like MLO-Y4 cells.Journal of bioenergetics and biomembranes · 2026Article
- Integrated multi-omics analysis reveals tumor-suppressive phenotypes and associated transcriptomic remodeling upon METTL3 overexpression in A549 lung cancer cells.Translational cancer research · 2026Article
- Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.Biomolecules · 2026Review
- RBM15 Enhances 5-Fluorouracil Drug Sensitivity and Suppresses Gastric Cancer Progression by Modulating N6-Methyladenosine Modification of ECT2-Dependent IGF2BP3.Research (Washington, D.C.) · 2026Article
- mFrontiers in immunology · 2026Review
- Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy.Journal of ovarian research · 2025Review
- Fat mass and obesity-associated protein downregulation enhances N6-methyladenosine methylation and drives ovarian cancer progression.Journal of cell communication and signaling · 2025Article
- Fuzheng Huayu recipe inhibits alveolar macrophage M2 polarization and oxidative phosphorylation via METTL3-mediated NDUFA2 m6A modification.Journal of bioenergetics and biomembranes · 2025Article
- MJournal of ovarian research · 2025Article
- Long non-coding RNA HCP5 accelerated malignant progression of ovarian cancer by inhibiting ferroptosis through interaction with polypyrimidine tract binding protein 1.Journal of ovarian research · 2025Article
- The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications.Biomarker research · 2025Review
- Emerging role of cancer-associated fibroblasts in the premetastatic niche.Molecular cancer · 2025Review
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.Journal of translational medicine · 2025Review
- The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer.Theranostics · 2025Article
- m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.Frontiers in immunology · 2025Review
- Anticancer effects of Erzhimaoling decoction in high-grade serous ovarian cancer in vitro and in vivo.European journal of medical research · 2024Article
- Enhancing mHeliyon · 2024Article
- Recent advances in understanding the immune microenvironment in ovarian cancer.Frontiers in immunology · 2024Review
- Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundOvarian cancer (OC) typically develops an immunosuppressive microenvironment by funtional changes of host immune cells. Dysregulated m6A level is associated with cancer progression via the intrinsic oncogenic pathways. However, the role of m6A in regulating host immune cell function during anti-tumor immunity needs comprehensive analysis. This study aimed to investigate the role of METTL3, a catalytic subunit of the methyltransferase complex, in regulating host immune cell response against OC.
methodsIn this study, myeloid-specific Mettl3 gene knockout (Mettl3-cKO) mice were bred using the Cre-LoxP system. Intraperitoneally injection of ID8 cells was used as a syngeneic OC model. Furthermore, the compositions of immune cell populations were analyzed by flow cytometry and single-cell sequencing. Moreover, chemokines and cytokines secretion were assessed using ELISA. Lastly, the role of METTL3 in regulating IL-1β secretion and inflammasome activation in bone marrow-derived macrophages cocultured with ID8 cells was specified by ELISA and immunoblotting.
resultsIt was revealed that OC cell growth was enhanced in Mettl3-cKO mice. Furthermore, a shift of decreased M1 to increased M2 macrophage polarization was observed during OC progression. Moreover, Mettl3 depletion in myeloid lineage cells increased secretion of CCL2 and CXCL2 in peritoneal lavage fluild. Interestingly, Mettl3 deficiency enhanced IL-1β secretion induced by viable ID8 cells independent of inflammasome activation and cell death. Therefore, OC cells in tumor-bearing mice trigger a slight inflammatory response with a low-to-moderate secretion of pro-inflammatory cytokines and chemokines.
conclusionThis study provides new insights into METTL3-mediated m6A methylation, which regulates host immune response against OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.